Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Open Access
- 1 October 2018
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (10) , e534-e545
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (C1060/A10334, C1060/A16464)
This publication has 106 references indexed in Scilit:
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- MRI for response assessment in metastatic bone diseaseEuropean Radiology, 2013
- Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan indexEJNMMI Research, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate CancerTheranostics, 2012
- Imaging metastatic bone disease from carcinoma of the prostateBritish Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cellsEndocrine-Related Cancer, 2007
- Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerNuklearmedizin-Nuclear Medicine, 2007
- Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastasesThe Prostate, 2005